Menu Search
Equities

Tsumura & Co

4540:TYO

Tsumura & Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,950.00
  • Today's Change54.00 / 1.39%
  • Shares traded142.60k
  • 1 Year change+41.93%
  • Beta0.7029
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Tsumura & Co have a median target of 4,890.00, with a high estimate of 5,300.00 and a low estimate of 4,400.00. The median estimate represents a 23.80% increase from the last price of 3,950.00.
High34.2%5,300.00
Med23.8%4,890.00
Low11.4%4,400.00

Dividends in JPY

In 2024, Tsumura & Co reported a dividend of 85.00 JPY, which represents a 32.81% increase over last year. The 3 analysts covering the company expect dividends of 136.00 JPY for the upcoming fiscal year, an increase of 60.00%.
Div growth (TTM)32.81%
More ▼

Earnings history & estimates in JPY

On Aug 05, 2024, Tsumura & Co reported 1st quarter 2025 earnings of 147.25 per share. This result exceeded the 93.54 expectation of the one analyst covering the company and exceeded last year's 1st quarter results by 90.37.
The next earnings announcement is expected on Nov 05, 2024.
Average growth rate+469.98%
Tsumura & Co reported annual 2024 earnings of 219.83 per share on May 09, 2024.
Average growth rate+5.94%
More ▼

Revenue history & estimates in JPY

Tsumura & Co. had 1st quarter 2025 revenues of 43.69m. This missed the 45.35m estimate of the one analyst following the company. This was 17.97% above the prior year's 1st quarter results.
Average growth rate+5.10%
Tsumura & Co. had revenues for the full year 2024 of 150.85m. This was 7.71% above the prior year's results.
Average growth rate+5.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.